A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
First in human, open-label, sequential dose escalation and expansion study of CPI-0610 in
patients with progressive lymphoma. CPI-0610 is a small molecule inhibitor of bromodomain and
extra-terminal (BET) proteins.